Dual and selective actions of glucocorticoids upon basal and stimulated growth hormone release in man.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this controlled clinical trial publication.

In humans, corticoids suppress growth and growth hormone (GH) secretion elicited by a variety of stimuli, while in the rat they potentiate both in vivo and in vitro GH release.

To further study this problem, growth-hormone-releasing hormone (GHRH) tests were performed in 6 nonobese Cushing's syndrome patients and 6 controls.

Who Took Part

The study group was 34 volunteers.

PubMed indexes the participants as adults, both men and women.

How the Study Was Run

In design terms this was a placebo-controlled study.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

What Was Measured

To further study this problem, growth-hormone-releasing hormone (GHRH) tests were performed in 6 nonobese Cushing's syndrome patients and 6 controls.

Topics PubMed links to this paper include Arginine, Clonidine, Cushing Syndrome, Dexamethasone, Growth Hormone, Growth Hormone-Releasing Hormone and Metyrapone.

What This Means in Plain Language

The paper is a placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 34 volunteers.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1990 (Neuroendocrinology), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.